STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3222 by analyst upside · 2026-08-14
RDY
Dr. Reddy's Laboratories Limited
Healthcare · Market Cap $10B · P/E 29.6x
ANALYST PRICE TARGET
+8.5%
implied upside to consensus target
Current Price $12.42
Consensus Target $13.48
Bull Target $15.77
Bear Target $11.39
Analysts Covering 5
ANALYST CONSENSUS - HOLD
Strong Buy
0
Buy
2
Hold
2
Sell
1
52-Week Low $11.36
52-Week High $15.67
YTD Return -9.8%
FUNDAMENTALS
Market Cap $10B
P/E Ratio (TTM) 29.6x
Forward P/E 19.1x
EPS (TTM) $0.42
PEG Ratio 1.64
Dividend Yield 0.67%
Revenue (TTM) $331.2B
Profit Margin 10.0%
52-WEEK RANGE
52-Week Low $11.36
52-Week High $15.67
Current Price $12.42
Bear Target $11.39
Bull Target $15.77
● Now $12.42 ● Target $13.48
TRADING DATA
Avg Volume 2.5M
YTD Return -9.8%
Analyst Count 5
Consensus Hold
Upside to Target +8.5%
Last Updated 2026-08-14

ANALYST SUMMARY

Dr. Reddy's Laboratories Limited (RDY) is currently trading at $12.42 with a Wall Street consensus price target of $13.48, implying potential upside of 8.5% over the next 12 months. 5 analysts currently cover RDY, with a consensus rating of Hold - 40% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $15.77, while the most cautious has a target of $11.39.

RDY operates in the Healthcare sector with a market capitalisation of $10B. The stock is down 9.8% year-to-date and is currently trading near the lower end of its 52-week range of $11.36 – $15.67.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for RDY, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HSBC ↑ Upgrade
Hold → Buy 2025-06-05 Building track record
Barclays - Reiterated
Overweight → Overweight 2024-11-06 Building track record
Barclays - Reiterated
Overweight → Overweight 2024-07-30 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
44
out of 100
Coverage depth
14/30
Consensus clarity
23/30
Vote unanimity
5/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →